Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 6/20 | 0.53 |
| ▸ | CTSK | P43235 | 4/20 | 0.53 |
| ▸ | CTSB | P07858 | 2/20 | 0.53 |
| ▸ | CTSL | P07711 | 2/20 | 0.53 |
| ▸ | KLK5 | Q9Y337 | 3/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | PSEN1 | P49768 | 4/20 | 0.47 |
| ▸ | PSEN2 | P49810 | 4/20 | 0.47 |
| ▸ | APH1B | Q8WW43 | 4/20 | 0.47 |
| ▸ | NCSTN | Q92542 | 4/20 | 0.47 |
| ▸ | APH1A | Q96BI3 | 4/20 | 0.47 |
| ▸ | PSENEN | Q9NZ42 | 4/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12709429 | 0.94 | CTSS (0.55) | CTSSCTSKCTSBCTSLKLK5 | |
| SCHEMBL5393279 | 0.89 | KLK5 (0.56) | CTSKKLK5ATMPSEN1PSEN2 | |
| SCHEMBL5393283 | 0.89 | KLK5 (0.56) | CTSKKLK5ATMPSEN1PSEN2 | |
| SCHEMBL5379412 | 0.88 | KLK5 (0.55) | CTSKKLK5ATMPSEN1PSEN2 | |
| SCHEMBL5379408 | 0.88 | KLK5 (0.55) | CTSKKLK5ATMPSEN1PSEN2 | |
| SCHEMBL5379746 | 0.87 | KLK5 (0.57) | CTSSCTSKKLK5ATMPSEN1 | |
| SCHEMBL7761083 | 0.87 | KLK5 (0.57) | CTSSCTSKKLK5ATMPSEN1 | |
| SCHEMBL5379743 | 0.87 | KLK5 (0.57) | CTSSCTSKKLK5ATMPSEN1 | |
| SCHEMBL1600553 | 0.87 | CTSS (0.51) | CTSSCTSKCTSBCTSLKLK5 | |
| SCHEMBL1600551 | 0.87 | CTSS (0.51) | CTSSCTSKCTSBCTSLKLK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7919523-B2 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS, INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-7919523-B2 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS, INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-20090042973-A1 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED | 2009-02-12 | — | — | US | disclosed |
| US-20090042973-A1 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED | 2009-02-12 | — | — | US | disclosed |
| US-7442718-B2 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-10-28 | — | — | US | disclosed |
| US-7442718-B2 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042973-A1 | Inhibitors of aspartyl protease | SPINT2, DNPEP, PRSS1 | CTSS 53/4885CTSK 211/4885CTSB 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.